Real-world Prevalence of Nonintegrase INSTI Resistance-Associated Mutations and Virological Outcomes in People Who Have Recently Acquired HIV-1 in the United Kingdom.

Abstract excerpt

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are the mainstay of antiretroviral therapy (ART) globally. Virological breakthrough is uncommon but often manifests as low-level viremia, and only 50% of cases have identified drug resistance mutations in the integrase gene. Nonintegrase mutations in the Gag-nucleocapsid protein (NC), envelope glycoprotein (Env), and 3' polypurine tract (3'PPT) have been...

Topics

Join the communities discussing this publication.

• Drug Resistance, Viral
• HIV-1
• HIV Infections
• HIV Integrase
• HIV Integrase Inhibitors